Nanjing Hicin Pharmaceutical Co Ltd Tangible Net Worth Ratio
Nanjing Hicin Pharmaceutical Co Ltd tangible net worth ratio. Nanjing Hicin Pharmaceutical Co Ltd (300584) has a Tangible Net Worth Ratio of 90.0% as of June 2026. This metric is calculated by deducting intangible assets (CN¥112.16 Million) from net assets (CN¥1.12 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore net asset growth rate of Nanjing Hicin Pharmaceutical Co Ltd to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Nanjing Hicin Pharmaceutical Co Ltd (2012–2025)
Tangible net worth ratio of Nanjing Hicin Pharmaceutical Co Ltd from 2012 to 2025. This chart shows how Nanjing Hicin Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 14 annual periods from 2012 to 2025. As of June 2026, the ratio stands at 90.0%, reflecting net assets of CN¥1.12 Billion with intangible assets of CN¥112.16 Million CNY. Check Nanjing Hicin Pharmaceutical Co Ltd (300584) strategic asset index to assess the company's strategic physical and investment asset allocation.
Nanjing Hicin Pharmaceutical Co Ltd Tangible Net Worth Ratio by Year (2012–2025)
Nanjing Hicin Pharmaceutical Co Ltd tangible net worth ratio by year from 2012 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for Nanjing Hicin Pharmaceutical Co Ltd from 2012 to 2025, covering 14 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see 300584 market cap.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 88.9% | CN¥1.10 Billion | CN¥121.74 Million | CN¥1.53 Billion | ▲ +3.5 pp |
| 2024 | 85.4% | CN¥1.04 Billion | CN¥151.40 Million | CN¥1.46 Billion | ▲ +2.5 pp |
| 2023 | 83.0% | CN¥987.50 Million | CN¥168.30 Million | CN¥1.41 Billion | ▲ +1.0 pp |
| 2022 | 82.0% | CN¥950.57 Million | CN¥171.34 Million | CN¥1.29 Billion | ▲ +0.2 pp |
| 2021 | 81.8% | CN¥948.48 Million | CN¥172.92 Million | CN¥1.30 Billion | ▲ +3.1 pp |
| 2020 | 78.7% | CN¥678.97 Million | CN¥144.73 Million | CN¥906.52 Million | ▼ -11.8 pp |
| 2019 | 90.5% | CN¥653.98 Million | CN¥61.91 Million | CN¥869.18 Million | ▼ -2.8 pp |
| 2018 | 93.3% | CN¥580.93 Million | CN¥38.87 Million | CN¥794.19 Million | ▼ -1.3 pp |
| 2017 | 94.7% | CN¥517.68 Million | CN¥27.67 Million | CN¥632.30 Million | ▲ +3.4 pp |
| 2016 | 91.3% | CN¥276.11 Million | CN¥24.09 Million | CN¥370.78 Million | ▲ +1.8 pp |
| 2015 | 89.5% | CN¥235.08 Million | CN¥24.73 Million | CN¥322.63 Million | ▲ +2.2 pp |
| 2014 | 87.3% | CN¥200.15 Million | CN¥25.37 Million | CN¥293.78 Million | ▼ -5.9 pp |
| 2013 | 93.2% | CN¥165.93 Million | CN¥11.22 Million | CN¥241.42 Million | ▲ +1.9 pp |
| 2012 | 91.3% | CN¥132.65 Million | CN¥11.48 Million | CN¥190.67 Million | — |